Therapeutic manipulation of the enteric microflora in inflammatory bowel diseases: Antibiotics, probiotics, and prebiotics

Gastroenterology

Volumn 126, Issue 6, 2004, Pages 1620-1633

  Sartor, R Balfour ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; ANTIBIOTIC AGENT; ANTIINFLAMMATORY AGENT; AZATHIOPRINE; CIPROFLOXACIN; CLARITHROMYCIN; COTRIMOXAZOLE; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; MERCAPTOPURINE; MESALAZINE; METHYLPREDNISOLONE; METRONIDAZOLE; OLIGOSACCHARIDE; ORNIDAZOLE; PREBIOTIC AGENT; PROBIOTIC AGENT; RIFAXIMIN; SYNBIOTIC AGENT; TACROLIMUS; TETRACYCLINE; TOBRAMYCIN; UNCLASSIFIED DRUG;

ANIMAL MODEL; ANTIBIOTIC THERAPY; ANUS FISTULA; BACTERIAL TRANSLOCATION; BIFIDOBACTERIUM; COLITIS; CROHN DISEASE; DIET THERAPY; DOSE TIME EFFECT RELATION; DRUG ACTIVITY; DRUG MECHANISM; ENTERITIS; GENETIC PREDISPOSITION; HUMAN; ILEITIS; ILEOCOLITIS; IMMUNE RESPONSE; INTESTINE FLORA; LACTOBACILLUS; LONG TERM CARE; NEUROPATHY; PARESTHESIA; PATHOGENESIS; PRIORITY JOURNAL; RELAPSE; REVIEW; SHORT COURSE THERAPY; ULCERATIVE COLITIS;

EID: 2442453484     PISSN: 00165085     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.gastro.2004.03.024     Document Type: Article

References (136)

1. Sartor RB. Microbial influences in inflammatory bowel disease: role in pathogenesis and clinical implications. In: Sartor RB, Sandbom WJ, eds. Kirsner's inflammatory bowel diseases. 6th ed. Edinburgh, Elsevier, 2003:138-162.
2. Podolsky DK. Inflammatory bowel disease. N Engl J Med 2002;347:417-429.
3. Isaacs KL, Sartor RB. Antibiotics in IBD. Gastroenterol Clin North Am 2004 (in press).
4. Linskens RK, Huijsdens XW, Savelkoul PH, Vandenbroucke-Grauls CM, Meuwissen SG. The bacterial flora in inflammatory bowel disease: current insights in pathogenesis and the influence of antibiotics and probiotics. Scand J Gastroenterol Suppl 2001;234:29-40.
5. Marteau P, Seksik P, Shanahan F. Manipulation of the bacterial flora in inflammatory bowel disease. Best Pract Res Clin Gastroenterol 2003;17:47-61.
6. Macfarlane GT, Cummings JH. Probiotics, infection and immunity. Curr Opin Infect Dis 2002;15:501-506.
7. Schultz M, Scholmerich J, Rath HC. Rationale for probiotic and antibiotic treatment strategies in inflammatory bowel diseases. Dig Dis 2003;21:105-128.
8. Biancone L, Monteleone I, Del Vecchio B, Vavassori P, Pallone F. Resident bacterial flora and immune system. Dig Liver Dis 2002;34(Suppl 2):S37-S43.
9. Cummings JH, Macfariane GT, Macfariane S. Intestinal bacteria and ulcerative colitis. Curr Issues Intest Microbiol 2003;4:9-20.
10. Guamer F, Casellas F, Borruel N, Antolin M, Videla S, Vilaseca J, Malagelada JR. Role of microecology in chronic inflammatory bowel diseases. Eur J Clin Nutr 2002;56(Suppl 4):S34-S38.
11. Wilson KH. Natural biota of the human gastrointestinal tract. In: Blaser MJ, Smith PD, Ravdin JI, Greenberg HB, Guerrant RL, eds. Infections of the gastrointestinal tract. 2nd ed. Philadelphia: Lippincott Williams & Wilkins, 2002:45-56.
12. Harper PH, Lee EC, Kettlewell MG, Bennett MK, Jewell DP. Role of the faecal stream in the maintenance of Crohn's colitis. Gut 1985;26:279-284.
13. D'Haens GR, Geboes K, Peeters M, Baert F, Penninckx F, Rutgeerts P. Early lesions of recurrent Crohn's disease caused by infusion of intestinal contents in excluded ileum. Gastroenterology 1998;114:262-267.
14. Swidsinski A, Ladhoff A, Pernthaler A, Swidsinski S, Loening-Baucke V, Ortner M, Weber J, Hoffmann U, Schreiber S, Dietel M, Lochs H. Mucosal flora in inflammatory bowel disease. Gastroenterology 2002;122:44-54.
15. Cartun RW, Van Kruiningen HJ, Pedersen CA, Berman MM. An immunocytochemical search for infectious agents in Crohn's disease. Mod Pathol 1993;6:212-219.
16. Ogura Y, Bonen DK, Inohara N, Nicolae DL, Chen F, Ramos R, Britton H, Moran T, Karaliuskas R, Duerr RH, Achkar JP, Brant SR, Bayless TM, Kirschner BS, Hanauer SB, Nunez G, Cho JH. A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease. Nature 2001;411:603-606.
17. Hugot JP, Chamaillard M, Zouali H, Lesage S, Cezard JP, Belaiche J, Almer S. Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. Nature 2001;411:599-603.
18. Girardin SE, Boneca IG, Viala J, Chamaillard M, Labigne A, Thomas G, Philpott DJ, Sansonetti PJ. Nod2 is a general sensor of peptidoglycan through muramyl dipeptide (MDP) detection. J Biol Chem 2003;278:8869-8872.
19. Hisamatsu T, Suzuki M, Relnecker HC, Nadeau WJ, McCormick BA, Podolsky DK. CARD15/NOD2 functions as an anti-bacterial factor in human intestinal epithelial cells. Gastroenterology 2003;124:993-1000.
20. Fellermann K, Wehkamp J, Herrlinger KR, Stange EF. Crohn's disease: a defensin deficiency syndrome? Eur J Gastroenterol Hepatol 2003;15:627-634.
21. Duchmann R, Kaiser I, Hermann E, Mayet W, Ewe K, Meyer zum Buschenfelde KH. Tolerance exists towards resident intestinal flora but is broken in active inflammatory bowel disease (IBD). Clin Exp Immunol 1995;102:448-455.
22. Macpherson A, Khoo UY, Forgacs I, Philpott-Howard J, Bjamason I. Mucosal antibodies in inflammatory bowel disease are directed against intestinal bacteria. Gut 1996;38:365-375.
23. Neut C, Bulols P, Desreumaux P, Membre JM, Lederman E, Gambiez L, Cortot A, Quandalle P, van Kruiningen H, Colombel JF. Changes in the bacterial flora of the neoterminal ileum after ileocolonic resection for Crohn's disease. Am J Gastroenterol 2002;97:939-946.
24. Rath HC, Herfarth HH, Ikeda JS, Grenther WB, Hamm TEJ, Balish E, Taurog JD, Hammer RE, Wilson KH, Sartor RB. Normal luminal bacteria, especially Bacteroides species, mediate chronic colitis, gastritis, and arthritis in HLA-B27/human beta2 microglobulin transgenic rats. J Clin Invest 1996;98:945-953.
25. Kim SC, Tonkonogy SL, Albright CA, Sartor RB. Regional and host specificity of colitis in mice monoassociated with different nonpathogenic bacteria (abstr). Gastroenterology 2003;124: A485.
26. Sellon RK, Tonkonogy S, Schultz M, Dieleman LA, Grenther W, Balish E, Rennick DM, Sartor RB. Resident enteric bacteria are necessary for development of spontaneous colitis and immune system activation in interleukin-10-deficient mice. Infect Immun 1998;66:5224-5231.
27. Castiglione F, Del Vecchio B, Rispo A, Petrelli G, Amalfi G, Cozzolino A, Cuccaro I, Mazzacca G. Orocecal transit time and bacterial overgrowth in patients with Crohn's disease. J Clin Gastroenterol 2000;31:63-66.
28. Castiglione F, Rispo A, Di Girolamo E, Cozzolino A, Manguso F, Grassia R, Mazzacca G. Antibiotic treatment of small bowel bacterial overgrowth in patients with Crohn's disease. Aliment Pharmacol Ther 2003;18:1107-1112.
29. Bemstein LH, Frank MS, Brandt LJ, Boley SJ. Healing of perineal Crohn's disease with metronidazole. Gastroenterology 1980;79:357-365.
30. Colombel JF, Cortot A, Van Kruiningen HJ. Antibiotics in Crohn's disease. Gut 2001;48:647.
31. Sartor RB. Microbial and dietary factors in the pathogenesis of chronic, immune-mediated intestinal inflammation. In: Blumberg RS, Neurath ME, eds. Immune mechanisms in inflammatory bowel diseases. 2004 (in press).
32. Present DH. How to do without steroids in inflammatory bowel disease. Inflamm Bowel Dis 2000;6:48-57.
33. Sartor RB. Antibiotics as therapeutic agents in Crohn's disease. In: Bayless TM, Hanauer S, eds. Current advanced therapy of inflammatory bowel disease. Hamilton, B.C. Decker, Inc., 2000:359-362.
34. Sutherland L, Singleton J, Sessions J, Hanauer S, Krawitt E, Rankin G, Summers R, Mekhjian H, Greenberger N, Kelly M. Double blind, placebo controlled trial of metronidazole in Crohn's disease. Gut 1991;32:1071-1075.
35. Ursing B, Alm T, Barany F, Bergelin I, Ganrot-Norlin K, Hoevels J, Huitfeldt B, Jarnerot G, Krause U, Krook A, Lindstrom B, Nordle O, Rosen A. A comparative study of metronidazole and sulfasalazine for active Crohn's disease: the cooperative Crohn's disease study in Sweden. II. Result. Gastroenterology 1982;83:550-562.
36. Greenbloom SL, Steinhart AH, Greenberg GR. Combination ciprofloxacin and metronidazole for active Crohn's disease. Can J Gastroenterol 1998;12:53-56.
37. Steinhart AH, Feagan BG, Wong CJ, Vandervoort M, Mikolainis S, Croitoru K, Seldman E, Leddin DJ, Bitton A, Drouln E, Cohen A, Greenberg GR. Combined budesonide and antibiotic therapy for active Crohn's disease: a randomized controlled trial. Gastroenterology 2002;123:33-40.
38. Rutgeerts P, Hiele M, Geboes K, Peeters M, Penninckx F, Aerts R, Kerremans R. Controlled trial of metronidazole treatment for prevention of Crohn's recurrence after ileal resection. Gastroenterology 1995;108:1617-1621.
39. Rutgeerts P, Van Assche G, D'Haens G, Baert F, Noman M, Aerden I, Geboes K, D'Hoore A, Penninckx F. Ornidazol for prophylaxis of postoperative Crohn's disease: final results of a double blind placebo controlled trial (abstr). Gastroenterology 2002;122:A80.
40. Krook A, Lindstrom B, Kjellander J, Jamerot G, Bodin L. Relation between concentrations of metronidazole and Bacteroides spp in faeces of patients with Crohn's disease and healthy individuals. J Clin Pathol 1981;34:645-650.
41. Colombel JF, Lemann M, Cassagnou M, Bouhnik Y, Duclos B, Dupas JL, Notteghem B, Mary JY. A controlled trial comparing ciprofloxacin with mesalamine for the treatment of active Crohn's disease. Groupe d'Etudes Therapeutiques des Affections Inflammatoires Digestives (GETAID). Am J Gastroenterol 1999;94:674-678.
42. Arnold GL, Beaves MR, Pryjdun VO, Mook WJ. Preliminary study of ciprofloxacin in active Crohn's disease. Inflamm Bowel Dis 2002;8:10-15.
43. Prantera C, Zannoni F, Scribano ML, Berto E, Andreoli A, Kohn A, Luzi C. An antibiotic regimen for the treatment of active Crohn's disease: a randomized, controlled clinical trial of metronidazole plus ciprofloxacin. Am J Gastroenterol 1996;91:328-332.
44. Prantera C, Berto E, Scribano ML, Falasco G. Use of antibiotics in the treatment of active Crohn's disease: experience with metronidazole and ciprofloxacin. Ital J Gastroenterol Hepatol 1998;30:602-606.
45. Leiper K, Morris AI, Rhodes JM. Open label trial of oral clarithromycin in active Crohn's disease. Aliment Pharmacol Ther 2000;14:801-806.
46. Shafran I, Johnson LK, Hamm L, Murdock RHJ. Efficacy and tolerability of rifaximin, a nonabsorbed oral antibiotic, in the treatment of active Crohn's disease: results of an open-label study (abstr). Am J Gastroenterol 2003;98:S250.
47. Borgaonkar MR, MacIntosh DG, Fardy JM. A meta-analysis of antimycobacterial therapy for Crohn's disease. Am J Gastroenterol 2000;95:725-729.
48. Gui GP, Thomas PR, Tizard ML, Lake J, Sanderson JD, Hermon-Taylor J. Two-year-outcomes analysis of Crohn's disease treated with rifabutin and macrolide antibiotics. J Antimicrob Chemother 1997;39:393-400.
49. Borody TJ, Leis S, Warren EF, Surace R. Treatment of severe Crohn's disease using antimycobacterial triple therapy - approaching a cure? Dig Liver Dis 2002;34:29-38.
50. Shafran I, Kugler L, el-Zaatari FA, Naser SA, Sandoval J. Open clinical trial of rifabutin and clarithromycin therapy in Crohn's disease. Dig Liver Dis 2002;34:22-28.
51. Schwartz DA, Pemberton JH, Sandborn WJ. Diagnosis and treatment of perianal fistulas in Crohn disease. Ann Intem Med 2001;135:906-918.
52. Brandt LJ, Bernstein LH, Boley SJ, Frank MS. Metronidazole therapy for perineal Crohn's disease: a follow-up study. Gastroenterology 1982;83:383-387.
53. Solomon MR, McLeod R. Combination ciprofloxacin and metronidazole in severe perianal Crohn's disease. Can J Gastroenterol 1993;7:571-573.
54. Gugler R, Jensen JC, Schulte H, Vogel R. The course of Crohn disease and side effect profile with long-term treatment using metronidazole. Z Gastroenterol 1989;27:676-682.
55. Burke DA, Axon AT, Clayden SA, Dixon MF, Johnston D, Lacey RW. The efficacy of tobramycin in the treatment of ulcerative colitis. Aliment Pharmacol Ther 1990;4:123-129.
56. Burke DA, Clayden SA, Dixon MF, Axon AT, Johnston D, Lacey RW. A follow up study of adjunctive oral tobramycin therapy in acute ulcerative colitis (abstr). Gastroenterology 1988;94:A55.
57. Danzl JT. Trimethoprim-sulphamethoxazole therapy of inflammatory bowel disease (abstr). Gastroenterology 1989;96:A110.
58. Turunen U, Farkkila MA, Valtonen V. Long-term treatment of ulcerative colitis with ciprofloxacin. Gastroenterology 1999;117:282-283.
59. Mantzaris GJ, Archavlis E, Christoforidis P, Kourtessas D, Amberiadis P, Florakis N, Petraki K, Spiliadi C, Triantafyllou G. A prospective randomized controlled trial of oral ciprofloxacin in acute ulcerative colitis. Am J Gastroenterol 1997;92:454-456.
60. Mantzaris GJ, Petraki K, Archavlis E, Amberiadis P, Kourtessas D, Christidou A, Triantafyllou G. A prospective randomized controlled trial of intravenous ciprofloxacin as an adjunct to corticosteroids in acute, severe ulcerative colitis. Scand J Gastroenterol 2001;36:971-974.
61. Lukas M, Konecny M, Zboril V. Rifaximin in patients with mild to moderate activity of ulcerative colitis: an open label study (abstr). Am J Gastroenterol 2003;98:A434.
62. Peppercorn MA. Are antibiotics useful in the management of nontoxic severe ulcerative colitis? J Clin Gastroenterol 1993;17:14-17.
63. Brigidi P, Swennen E, Rizzello F, Bozzolasco M, Matteuzzi D. Effects of rifaximin administration on the intestinal microbiota in patients with ulcerative colitis. J Chemother 2002;14:290-295.
64. Madden MV, McIntyre AS, Nicholls RJ. Double-blind crossover trial of metronidazole versus placebo in chronic unremitting pouchitis. Dig Dis Sci 1994;39:1193-1196.
65. Gionchetti P, Amadini C, Rizzello F, Venturi A, Poggioli G, Campieri M. Diagnosis and treatment of pouchitis. Best Pract Res Clin Gastroenterol 2003;17:75-87.
66. Shen B, Achkar JP, Lashner BA, Ormsby AH, Remzi FH, Brzezinski A, Bevins CL, Bambrick ML, Seidner DL, Fazio VW. A randomized clinical trial of ciprofloxacin and metronidazole to treat acute pouchitis. Inflamm Bowel Dis 2001;7:301-305.
67. Gionchetti P, Rizzello F, Venturi A, Ugolini F, Rossi M, Brigidi P, Johansson R, Ferrieri A, Poggioli G, Campieri M. Antibiotic combination therapy in patients with chronic, treatment-resistant pouchitis. Aliment Pharmacol Ther 1999;13:713-718.
68. Rath HC, Schultz M, Freitag R, Dieleman LA, Li F, Linde HJ, Scholmerich J, Sartor RB. Different subsets of enteric bacteria induce and perpetuate experimental colitis in rats and mice. Infect Immun 2001;69:2277-2285.
69. Madsen KL, Doyle JS, Tavernini MM, Jewell LD, Rennie RP, Fedorak RN. Antibiotic therapy attenuates colitis in interleukin 10 gene-deficient mice. Gastroenterology 2000;118:1094-1055.
70. Hoentjen F, Harmsen HJ, Braat H, Torrice CD, Mann BA, Sartor RB, Dieleman LA. Antibiotics with a selective aerobic or anaerobic spectrum have different therapeutic activities in various regions of the colon in interleukin-10 gene deficient mice. Gut 2003;52:1721-1727.
71. Fiorucci S, Distrutti E, Mencarelli A, Barbanti M, Palazzini E, Morelli A. Inhibition of intestinal bacterial translocation with rifaximin modulates lamina propria monocytic cells reactivity and protects against inflammation in a rodent model of colitis. Digestion 2002;66:246-256.
72. Bamias G, Marini M, Moskaluk CA, Odashima M, Ross WG, Rivera-Nieves J, Cominelli F. Down-regulation of intestinal lymphocyte activation and Th1 cytokine production by antibiotic therapy in a murine model of Crohn's disease. J Immunol 2002;169:5308-5314.
73. Yamada T, Deitch E, Specian RD, Perry MA, Sartor RB, Grisham MB. Mechanisms of acute and chronic intestinal inflammation induced by indomethacin. Inflammation 1993;17:641-662.
74. Onderdonk AB, Hermos JA, Dzink JL, Bartlett JG. Protective effect of metronidazole in experimental ulcerative colitis. Gastroenterology 1978;74:521-526.
75. Videla S, Vilaseca J, Guamer F, Salas A, Treserra F, Crespo E, Antolin M, Malagelada JR. Role of intestinal microflora in chronic inflammation and ulceration of the rat colon. Gut 1994;35:1090-1097.
76. Dieleman LA, Goerres M, Arends A, Sprengers D, Torrice C, Hoentjen F, Grenther WB, Sartor RB. Lactobacillus GG prevents recurrence of colitis in HLA-B27 transgenic rats after antibiotic treatment. Gut 2003;52:370-376.
77. Gionchetti P, Rizzello F, Venturi A, Brigidi P, Matteuzzi D, Bazzocchi G, Poggioli G, Miglioli M, Campieri M. Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: a double-blind, placebo-controlled trial. Gastroenterology 2000;119:305-309.
78. Schultz M, Rath HC. The possible role of probiotic therapy in inflammatory bowel disease. In: Tannock GW, ed. Probiotics and prebiotics: where are we going? Wymondham, UK: Caister Academic Press, 2002:175-237.
79. Shanahan F. Probiotics and inflammatory bowel disease: from fads and fantasy to facts and future. Br J Nutr 2002;88(suppl 1):S5-S9.
80. Shanahan F. Probiotics: a perspective on problems and pitfalls. Scand J Gastroenterol Suppl 2003;237:34-36.
81. Hart AL, Kamm MA. Use of probiotics in the treatment of inflammatory bowel disease. J Clin Gastroenterol 2003;36:111-119.
82. Famularo G, Mosca L, Minisola G, Trinchieri V, De Simone C. Probiotic lactobacilli: a new perspective for the treatment of inflammatory bowel disease. Curr Pharm Des 2003;9:1973-1980.
83. Mimura T, Rizzello F, Schreiber S, Talbot IC, Nicholls RJ, Gionchetti P, Campieri M, Kamm MA. Once daily high dose probiotic therapy maintains remission and improved quality of life in patients with recurrent or refractory pouchitis: a randomised, placebo-controlled, double-blind trial (abstr). Gastroenterology 2002;122:A81.
84. Gionchetti P, Rizzello F, Helwig U, Venturi A, Lammers KM, Brigidi P, Vitali B, Poggioli G, Miglioli M, Campieri M. Prophylaxis of pouchitis onset with probiotic therapy: a double-blind placebo controlled trial. Gastroenterology 2003;124:1202-1209.
85. Kruis W, Schutz E, Fric P, Fixa B, Judmaier G, Stolte M. Double-blind comparison of an oral Escherichia coli preparation and mesalazine in maintaining remission of ulcerative colitis. Aliment Pharmacol Ther 1997;11:853-858.
86. Rembacken BJ, Snelling AM, Hawkey PM, Chalmers DM, Axon AT. Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomised trial. Lancet 1999;354:635-639.
87. Kruis W, Kalk EK, Fric P, Stolte M. Maintenance of remission in ulcerative colitis is equally effective with Escherichia coli Nissle 1917 and with standard mesalamine (abstr). Gastroenterology 2001;120:A127.
88. Ishikawa H, Akedo I, Umesaki Y, Tanaka R, Imaoka A, Otani T. Randomized controlled trial of the effect of bifidobacteria-fermented milk on ulcerative colitis. J Am Coll Nutr 2003;22:56-63.
89. Venturi A, Gionchetti P, Rizzello F, Johansson R, Zucconi E, Brigidi P, Matteuzzi D, Campieri M. Impact on the composition of the faecal flora by a new probiotic preparation: preliminary data on maintenance treatment of patients with ulcerative colitis. Aliment Pharmacol Ther 1999;13:1103-1108.
90. Fedorak RN, Gionchetti P, Campieri M, De Simone C, Madsen K, Isaacs KL, Sartor RB. VSL3 probiotic mixture induces remission in patients with active ulcerative colitis (abstr). Gastroenterology 2003;124:A377.
91. Guslandi M, Giollo P, Testoni PA. A pilot trial of Saccharomyces boulardii in ulcerative colitis. Eur J Gastroenterol Hepatol 2003;15:697-698.
92. Borody TJ, Warren EF, Leis S, Surace R, Ashman O. Treatment of ulcerative colitis using fecal bacteriotherapy. J Clin Gastroenterol 2003;37:42-47.
93. Malchow HA. Crohn's disease and Escherichia coli. A new approach in therapy to maintain remission of colonic Crohn's disease? J Clin Gastroenterol 1997;25:653-658.
94. Prantera C, Scribano ML, Falasco G, Andreoli A, Luzi C. Ineffectiveness of probiotics in preventing recurrence after curative resection for Crohn's disease: a randomised controlled trial with Lactobacillus GG. Gut 2002;51:405-409.
95. Guandalini S. Use of Lactobacillus-GG in paediatric Crohn's disease. Dig Liver Dis 2002;34(suppl 2):S63-S65.
96. Madsen KL, Doyle JS, Jewell LD, Tavernini MM, Fedorak RN. Lactobacillus species prevents colitis in interleukin 10 gene-deficient mice. Gastroenterology 1999;116:1107-1114.
97. Madsen K, Cornish A, Soper P, McKaigney C, Jijon H, Yachimec C, Doyle J, Jewell L, De Simone C. Probiotic bacteria enhance murine and human intestinal epithelial barrier function. Gastroenterology 2001;121:580-591.
98. Schultz M, Veltkamp C, Dieleman LA, Grenther WB, Wyrick PB, Tonkonogy SL, Sartor RB. Lactobacillus plantarum 299V in the treatment and prevention of spontaneous colitis in interleukin-10 deficient mice. Inflamm Bowel Dis 2002;8:71-80.
99. McCarthy J, O'Mahony L, O'Callaghan L, Sheil B, Vaughan EE, Fitzsimons N, Fitzgibbon J, O'Sullivan GC, Kiely B, Collins JK, Shanahan F. Double blind, placebo controlled trial of two probiotic strains in interleukin 10 knockout mice and mechanistic link with cytokine balance. Gut 2003;52:975-980.
100. Steidler L, Hans W, Schotte L, Neirynck S, Obermeier F, Falk W, Fiers W, Remaut E. Treatment of murine colitis by Lactococcus lactis secreting interleukin-10. Science 2000;289:1352-1355.
101. Shiba T, Aiba Y, Ishikawa H, Ushiyama A, Takagi A, Mine T, Koga Y. The suppressive effect of bifidobacteria on Bacteroides vulgatus, a putative pathogenic microbe in inflammatory bowel disease. Microbiol Immunol 2003;47:371-378.
102. Rath HC, Wilson KH, Sartor RB. Differential induction of colitis and gastritis in HLA-B27 transgenic rats selectively colonized with Bacteroides vulgatus and Escherichia coli. Infect Immun 1999;67:2969-2974.
103. Boudeau J, Glasser AL, Julien S, Colombel JF, Darfeuille-Michaud A. Inhibitory effect of probiotic Escherichia coli strain Nissle 1917 on adhesion to and invasion of intestinal epithelial cells by adherent-invasive E. coli strains isolated from patients with Crohn's disease. Aliment Pharmacol Ther 2003;18:45-56.
104. Mack DR, Michail S, Wei S, McDougall L, Hollingsworth MA. Probiotics inhibit enteropathogenic E. coli adherence in vitro by inducing intestinal mucin gene expression. Am J Physiol 1999;276:G941-G950.
105. Trivedi K, Barrett KE, Resta-Lenert SC. Probiotic inhibition of the entry of enteroinvasive E. coli into human intestinal epithelial cells involves both Rho-dependent and independent pathways (abstr). Gastroenterology 2003;124:A106.
106. Mattar AF, Teitelbaum DH, Drongowski RA, Yongyi F, Harmon CM, Coran AG. Probiotics up-regulate MUC-2 mucin gene expression in a Caco-2 cell-culture model. Pediatr Surg Int 2002;18:586-590.
107. Pavan S, Desreumaux P, Mercenier A. Use of mouse models to evaluate the persistence, safety, and immune modulation capacities of lactic acid bacteria. Clin Diagn Lab Immunol 2003;10:696-701.
108. Mattar AF, Drongowski RA, Coran AG, Harmon CM, Effect of probiotics on enterocyte bacterial translocation in vitro. Pediatr Surg Int 2001;17:265-268.
109. Ulisse S, Gionchetti P, D'Alo S, Russo FP, Pesce I, Ricci G, Rizzello F, Helwig U, Cifone MG, Campieri M, De Simone C. Expression of cytokines, inducible nitric oxide synthase, and matrix metalloproteinases in pouchitis: effects of probiotic treatment. Am J Gastroenterol 2001;96:2691-2699.
110. Pathmakanthan S, Li CK, Cowie J, Hawkey CJ. Lactobacillus plantarum 299: beneficial in vitro immunomodulation in cells extracted from inflamed human colon. J Gastroenterol Hepatol 2004;19:166-173.
111. Borruel N, Carol M, Casellas F, Antolin M, de Lara F, Espin E, Naval J, Guarner F, Malagelada JR. Increased mucosal tumour necrosis factor alpha production in Crohn's disease can be downregulated ex vivo by probiotic bacteria. Gut 2002;51:659-664.
112. Cender CJ, Haller D, Walters C, Sartor RB. VSL #3 alters cytokine production of unfractionated splenocytes upon stimulation with cecal bacterial lysate: immunomodulation by this probiotic combination (abstr). Gastroenterology 2002;122:A145.
113. Jijon HB, Backer J, Diaz H, Yeung H, Thiel D, McKaigney C, De Simone C, Madsen K. DNA from probiotic bacteria modulates murine and human epithelial and immune function. Gastroenterology 2004;126 (in press).
114. Yan F, Polk DB. Probiotic bacterium prevents cytokine-induced apoptosis in intestinal epithelial cells. J Biol Chem 2002;277:50959-50965.
115. Rachmilewitz D, Katakara K, Karmeli F, Hayashi T, Reinus C, Akira S, Lee J, Takabayashi K, Takeda K, Raz E. Toll-like receptor 9 signaling mediates the anti-inflammatory effects of probiotics in murine experimental colitis. Gastroenterology 2004;126:520-528.
116. Cummings JH. Dietary carbohydrates and the colonic microflora. Curr Opin Clin Nutr Metab Care 1998;1:409-414.
117. Bird AR, Brown IL, Topping DL. Starches, resistant starches, the gut microflora and human health. Curr Issues Intest Microbiol 2000;1:25-37.
118. Jacobasch G, Schmiedl D, Kruschewski M, Schmehl K. Dietary resistant starch and chronic inflammatory bowel diseases. Int J Colorectal Dis 1999;14:201-211.
119. Kanauchi O, Mitsuyama K, Homma T, Takahama K, Fujiyama Y, Andoh A, Araki Y, Suga T, Hibi T, Naganuma M, Asakura H, Nakano H, Shimoyama T, Hida N, Haruma K, Koga H, Sata M, Tomiyasu N, Toyonaga A, Fukuda M, Kojima A, Bamba T. Treatment of ulcerative colitis patients by long-term administration of germinated barley foodstuff: multi-center open trial. Int J Mol Med 2003;12:701-704.
120. Bamba T, Kanauchi O, Andoh A, Fujiyama Y. A new prebiotic from germinated barley for nutraceutical treatment of ulcerative colitis. J Gastroenterol Hepatol 2002;17:818-824.
121. Mitsuyama K, Toyonaga A, Sata M. Intestinal microflora as a therapeutic target in inflammatory bowel disease. J Gastroenterol 2002;37(Suppl 14):73-77.
122. Kanauchi O, Suga T, Tochihara M, Hibi T, Naganuma M, Homma T, Asakura H, Nakano H, Takahama K, Fujiyama Y, Andoh A, Shimoyama T, Hida N, Haruma K, Koga H, Mitsuyama K, Sata M, Fukuda M, Kojima A, Bamba T. Treatment of ulcerative colitis by feeding with germinated barley foodstuff: first report of a multicenter open control trial. J Gastroenterol 2002;37:67-72.
123. Hallert C, Kaldma M, Petersson BG. Ispaghula husk may relieve gastrointestinal symptoms in ulcerative colitis in remission. Scand J Gastroenterol 1991;26:747-750.
124. Videla S, Vilaseca J, Antolin M, Garcia-Lafuente A, Guarner F, Crespo E, Casalots J, Salas A, Malagelada JR. Dietary inulin improves distal colitis induced by dextran sodium sulfate in the rat. Am J Gastroenterol 2001;96:1486-1493.
125. Araki Y, Andoh A, Koyama S, Fujiyama Y, Kanauchi O, Bamba T. Effects of germinated barley foodstuff on microflora and short chain fatty acid production in dextran sulfate sodium-induced colitis in rats. Biosci Biotechnol Biochem 2000;64:1794-1800.
126. Fukuda M, Kanauchi O, Araki Y, Andoh A, Mitsuyama K, Takagi K, Toyonaga A, Sata M, Fujiyama Y, Fukuoka M, Matsumoto Y, Bamba T. Prebiotic treatment of experimental colitis with germinated barley foodstuff: a comparison with probiotic or antibiotic treatment. Int J Molec Med 2002;9:65-70.
127. Kanauchi O, Serizawa I, Araki Y, Suzuki A, Andoh A, Fujiyama Y, Mitsuyama K, Takaki K, Toyonaga A, Sata M, Bamba T. Germinated barley foodstuff, a prebiotic product, ameliorates inflammation of colitis through modulation of the enteric environment. J Gastroenterol 2003;38:134-141.
128. Cherbut C, Michel C, Lecannu G. The prebiotic characteristics of fructooligosaccharides are necessary for reduction of TNBS-induced colitis in rats. J Nutr 2003;133:21-27.
129. Moreau NM, Martin LJ, Toquet CS, Laboisse CL, Nguyen PG, Siliart BS, Dumon HJ, Champ MM. Restoration of the integrity of rat caeco-colonic mucosa by resistant starch, but not by fructooligosaccharides, in dextran sulfate sodium-induced experimental colitis. Br J Nutr 2003;90:75-85.
130. Holma R, Juvonen P, Asmawi MZ, Vapaatalo H, Korpela R. Galacto-oligosaccharides stimulate the growth of bifidobacteria but fall to attenuate inflammation in experimental colitis in rats. Scand J Gastroenterol 2002;37:1042-1047.
131. Hoentjen F, Zhang X, Tannock GW, Dieleman LA. The prebiotic combination inulin and oligofructose prevents colitis in HLA-B27 transgenic rats (abstr). Gastroenterology 2004;126 (in press).
132. Kleessen B, Hartmann L, Blaut M, Oligofructose and long-chain inulin: influence on the gut microbial ecology of rats associated with a human faecal flora. Br J Nutr 2001;86:291-300.
133. Hopkins MJ, Macfarlane GT. Nondigestible oligosaccharides enhance bacterial colonization resistance against Clostridium difficile in vitro. Appl Environ Microbiol 2003;69:1920-1927.
134. Casellas F, Borruel N, Papo M, Guamer F, Antolin M, Videla S, Malagelada JR. Antiinflammatory effects of enterically coated amoxicillin-clavulanic acid in active ulcerative colitis. Inflamm Bowel Dis 1998;4:1-5.
135. Plein K, Hotz J. Therapeutic effects of Saccharomyces boulardil on mild residual symptoms in a stable phase of Crohn's disease with special respect to chronic diarrhea - a pilot study. Z Gastroenterol 1993;31:129-134.
136. Guslandi M, Mezzi G, Sorghi M, Testoni PA. Saccharomyces boulardii in maintenance treatment of Crohn's disease. Dig Dis Sci 2000;45:1462-1464.